H.
Christopher Owings
Assistant
Director
Division
of Corporation Finance
Securities
and Exchange Commission
100
F Street, NE
Mail
Stop #3561
Washington,
DC 20549
|
37.
|
We
note your presentation of the non-GAAP measure "Average retail gross
margin per MWh without fair value impacts." In arriving at this measure,
it appears you exclude an item that is recurring in nature. Please
note
that if you present a non-GAAP performance measure that excludes
items of
a recurring nature, you should include disclosure to demonstrate
the
usefulness of the measure. In this regard, please fully address the
bullet
points in Question 8 of our "Frequently Asked Questions Regarding
the Use
of Non-GAAP Financial Measures," available on our website at www.sec.gov,
in crafting your revised disclosure. In this regard, ensure you revise
your disclosure as
follows:
|
·
|
Disclose
how you use the non-GAAP measure to conduct or evaluate your
business.
|
·
|
Discuss
the economic substance behind your decision to use the
measure.
|
·
|
Disclose
the material limitations associated with use of the measure as compared
to
the use of the most directly comparable GAAP financial
measure.
|
·
|
Disclose
the manner in which you compensate for these limitations when using
the
measure.
|
·
|
Disclose
the substantive reasons why you believe the measures provide useful
information to
investors.
|
|
|
|
||||||||||
|
2006
|
2005
|
2004
|
|||||||||
Average
retail gross margin per MWh
|
$
|
2.52
|
$
|
5.19
|
$
|
6.01
|
||||||
Change
in fair value related to non-hedging energy
|
||||||||||||
contracts
and from cash flow hedge ineffectiveness
|
(3.41)
|
0.12
|
0.08
|
|||||||||
Average
retail gross margin per MWh without
|
||||||||||||
fair
value impacts
|
$
|
5.93
|
$
|
5.07
|
$
|
5.93
|
38.
|
You
disclose that none of your outstanding debt requires the acceleration
of
interest or principal payments in the event of a ratings downgrade,
unless
the downgrade occurs in the context of a merger, consolidation or
sale. In
this regard, please explain to us, with a view toward expanding your
discussion, the consequences of a ratings downgrade in connection
with the
acquisition of
Aquila.
|
39.
|
With
respect to the "As Adjusted 2005" and "As Adjusted 2004" columns,
please
consider including a note reference to where the change in accounting
principle is discussed. Also consider the effect on other financial
statements presented. Refer to Illustration 1 in Appendix A of SFAS
154.
Additionally, please include discussion in management's discussion
and
analysis to clearly explain why prior periods are
adjusted.
|
40.
|
We
note that the line item "Other" represents a significant portion
of total
operating expenses. Please separately present each material item
comprising "Other" or confirm to us that there are no such material
items
pursuant to Rule 5¬03(b) 2-6 of Regulation S-X. Also provide us with such
information.
|
|
2006
|
2005
|
2004
|
|||||||||
(thousands)
|
||||||||||||
Operating
expenses - KCP&L
|
$
|
260,259
|
$
|
263,438
|
$
|
256,509
|
||||||
Selling,
general and administrative - non-regulated
|
67,658
|
64,363
|
67,154
|
|||||||||
Total
|
$
|
327,917
|
$
|
327,801
|
$
|
323,663
|
||||||
reported
in 10-K "Other" operating expenses
|
$
|
327,917
|
$
|
327,801
|
$
|
323,663
|
41.
|
Please
note that we do not believe SFAS 95 supports aggregating operating,
investing, and financing cash flows from discontinued operations
into a
single line item. In this regard, in accordance with footnote 10
to
paragraph 26 of SFAS 95, please revise your presentation of cash
flows
from discontinued operations to
either:
|
·
|
combine
cash flows generated from discontinued operations with the cash flows
from
continuing operations within each of the three
categories,
|
·
|
separately
identify cash flows related to discontinued operations within each
of the
three categories, or
|
·
|
display
the cash flows related to discontinued operations separately for
operating, investing and financing activities near the bottom of
.the
statement, just before "net change in cash and cash
equivalents.”
|
|
2005
|
2004
|
||||||
(thousands)
|
||||||||
Net
Change in Cash and Cash Equivalents
|
(24,687 | ) |
13,360
|
|||||
Cash
and Cash Equivalents at Beginning of Year (includes $626 and
$168
|
||||||||
of
cash included in assets of discontinued operations in 2005 and 2004,
respectively)
|
127,755
|
114,395
|
||||||
Cash
and Cash Equivalents at End of Year (includes $626 of cash
included in assets
|
||||||||
of
discontinued operations in 2004)
|
$
|
103,068
|
$
|
127,755
|
42.
|
We
acknowledge a letter dated October 14, 2005 in which you detailed
the
relevancy of SFAS 115 disclosures. Please note the staff's view
that the major disclosure requirements of Statement 115 should be
provided. Accordingly, please note the requirements to disclose
maturity information as well as unrealized gains/losses by security
type.
|
43.
|
Based
on your 2006 annual impairment test, please tell us whether the fair
value
as determined exceeded the carrying amount of the tested
assets. If not, please provide us with step 2 of the analysis
as discussed in paragraph 20 of SFAS 142. In any event, please
provide us with the fair value of the tested reporting unit for the
2005
and 2006 tests.
|
44.
|
Please
reconcile the adjustment to accumulated OCI presented in the table
on page
92 to the SFAS 158 adjustments presented in your statement of common
shareholders' equity on page 63. Additionally, help us understand
the
relationship between the post SFAS 158 regulatory asset disclosed
in the
table for 2006 and the regulatory asset, net, disclosed on page
93. Similarly tell us why the 2005 regulatory asset on page 93
differs from the pension and post-retirement obligations on page
88. If
due to post-retirement obligations, tell us why it does not differ
for
2006.
|
|
2006
|
|||
(Millions)
|
||||
To
record SFAS No. 158
|
$
|
170.2
|
||
Transfer
of OCI charge to regulatory asset
|
(155.7 | ) | ||
Reversal
of deferred taxes
|
(12.9 | ) | ||
OCI
recorded for unregulated companies
|
$
|
1.6
|
45.
|
Please
disclose the net periodic benefit cost for KCP&L for each period
presented.
|
46.
|
Please
explain to us and disclose how you calculate the market related value
of
plan assets as that term is defined in SFAS 81. Since there is an
alternative to how you can calculate this item, and it has a direct
effect
on pension expense, we believe you should disclose how you determine
this
amount in accordance with paragraph 12 of APB
22.
|
47.
|
Please
provide us with your probability assessment regarding the future
recovery
of your pension and post retirement cost regulatory asset. In your
response, please tell us how pension costs are recovered in rates,
including the relationship between amounts included in rates versus
the
SFAS 87 expense. Please tell us whether contributions to the
pension trust are in any way related to recovery
amounts.
|
48.
|
Please
explain to us your basis in GAAP for subtracting the present value
of
dividends in calculating stock compensation expense for performance
shares
and restricted stock. Please tell us in greater detail how you account
for
the accrued reinvested dividends in performance versus restricted
share
grants, including how you determine the number of restricted shares
to be
issued in lieu of cash dividends. A comprehensive example may
clarify our understanding. If not done in the preceding manner,
ensure your response explains the difference, if any, in the expense
recognition for performance shares versus restricted
stock.
|
|
|
|
|
|
|
|
|
|
||
Grant
Shares:
|
1,000
|
|
||||||||
Fair
Market Value of common stock at time of grant:
|
$30
|
|
||||||||
Fair
Market Value of common stock at end of award or vesting
period:
|
$40
|
|
||||||||
Dividends
per quarter per share:
|
$0.415
|
|
||||||||
NPV
of dividends (3 year period):
|
$3.73
|
|
||||||||
Risk-free
rate
|
4.77%
|
|
||||||||
Vesting
or Award period:
|
3
years
|
|
||||||||
|
|
|||||||||
Performance
Shares
|
|
|||||||||
Dividend
Accrual:
|
|
|||||||||
Performance
at Target (100%)
|
1,000
|
Shares
Earned
|
|
|||||||
|
|
|||||||||
|
1,000
|
X
|
$40
|
=
|
$40,000
|
|
||||
|
$40,000
|
/
|
$30
|
=
|
1,333
|
shares-common stock
|
||||
|
1,333
|
X
|
$0.415
|
=
|
$553.20
|
quarterly dividends accrued and paid in
cash upon vesting
|
||||
|
||||||||||
Expense
Recognition
|
|
|||||||||
|
(A)
|
(B)
|
(A)*(B)
|
|
||||||
Condition
|
Shares
granted
|
Shares
earned
|
Grant
date price less NPV of dividends
($30-$3.73)
|
To
be expensed over award period
|
|
|||||
Market*
|
500
|
500
|
$26.27
|
$ 13,135.00
|
|
|||||
Performance**
|
500
|
400
|
$26.27
|
$ 10,508.00
|
|
|||||
|
1,000
|
Total
|
$ 23,643.00
|
|
||||||
|
|
|||||||||
|
Annual
expense
|
$ 23,643.00
|
/
|
3
years
|
=
|
$ 7,881.00
|
|
|||
*
100% target
|
|
|||||||||
**Updated
quarterly based on results of evaluation of criteria
|
|
|||||||||
|
|
|||||||||
Restricted
Stock
|
|
|||||||||
Number
of Restricted Shares Issued in Lieu of Cash
|
|
|||||||||
|
Total
Shares before Quarterly Dividend
|
Dividend
|
Dividend
$
|
Share
Price
(at
time of dividend payment)
|
Shares
Repurchased
|
Total
Shares after Quarterly Dividend
|
||||
1st
quarter
|
1,000
|
X
|
$0.415
|
=
|
$ 415.00
|
/
|
$35
|
=
|
11.86
|
1,011.86
|
2nd
quarter
|
1,011.86
|
X
|
$0.415
|
=
|
$ 419.92
|
/
|
$37
|
=
|
11.35
|
1,023.21
|
3rd
quarter
|
1,023.21
|
X
|
$0.415
|
=
|
$ 424.63
|
/
|
$39
|
=
|
10.89
|
1,034.09
|
4th
quarter
|
1,034.09
|
X
|
$0.415
|
=
|
$ 429.15
|
/
|
$40
|
=
|
10.73
|
1,044.82
|
|
|
|||||||||
Expense
Recognition
|
|
|||||||||
|
(A)
|
(B)
|
(A)*(B)
|
|
||||||
|
Shares
granted
|
Grant
date price less NPV of dividends
($30-$3.73)
|
To
be expensed over vesting period
|
|
||||||
|
1,000
|
$26.27
|
$ 26,270.00
|
|
||||||
|
|
|||||||||
|
|
|
Annual
expense
|
|
$ 26,270.00
|
/
|
3
years
|
=
|
$ 8,756.67
|
|
49.
|
Given
maturity dates of 20l5 and 2017, please explain to us why certain
EIRR
bonds are classified as current
liabilities.
|
50.
|
Please
tell us in detail how you accounted for the forward sale agreement
during
its term and upon settlement. Tell us the basis in GAAP for your
accounting. We assume the forward was not considered a derivative
based on
paragraph 11.a of SFAS 133. If so, tell us how the contract was
indexed to Great Plains common stock. If otherwise, please
clarify our understanding. Finally, tell us how you settled the
contract and the final
accounting.
|
51.
|
With
respect to your preferred stock, please provide all disclosures required
by paragraph 4 of SFAS 129. Specifically address the
liquidation value. If it is the same as redemption value, so state
in
future filings. Additionally, explain to us the meaning of your statement
that you have the option to redeem preferred stock at prices
"approximating" par or stated
value.
|
52.
|
On
page 19, you disclose that you own 55% of Iatan No.2. We note this
plant
will not be placed in service until 2010. Nonetheless, in accordance
with
SAB Topic 10:C, please disclose your percentage interest and the
amount of
plant under construction in the
footnotes.
|